| At 3L initiation |
| Demographic characteristics |
| Age, years; mean ± SD [median] |
58.52±13.88 [58.00] |
70.34±12.12 [72.00] |
| <65 years, n (%) |
208 (70.3) |
NA |
| 65+ years, n (%) |
88 (29.7) |
NA |
| Female, n (%) |
147 (49.7) |
21 (39.6) |
| White (race/ethnicity),b n (%) |
— |
44 (83.0) |
| Census region of residence,c n (%) |
| South |
120 (40.5) |
16 (30.2) |
| Midwest/North Central |
81 (27.4) |
NA |
| Northeast |
44 (14.9) |
NA |
| West |
51 (17.2) |
19 (35.8) |
| Commercial health plan typed, n (%) |
| Preferred provider organization |
148 (50.0) |
— |
| Medicare supplemental coverage |
89 (30.1) |
— |
| Comprehensive |
56 (18.9) |
— |
| Home maintenance organization |
43 (14.5) |
— |
| Other |
44 (14.9) |
— |
| Unknown |
5 (1.7) |
— |
| Calendar year of first CML diagnosis,e n (%) |
| 2001-2004 |
9 (3.0) |
NA |
| 2005-2008 |
55 (18.6) |
NA |
| 2009-2012 |
120 (40.5) |
NA |
| 2013-2018 |
112 (37.8) |
20 (37.7) |
| During the 6-month period prior to specific therapy initiation |
| Modified CCI, excluding CML,f mean ± SD [median] |
1.64±1.69 [2.00] |
3.60±2.31 [3.00] |
| Darkow Disease Complexity Index,g n (%) |
| Mild |
106 (35.8) |
NA |
| Moderate |
104 (35.1) |
NA |
| Severeh |
86 (29.1) |
24 (45.3) |
| Use of hydroxyurea (pre-treatment), n (%) |
21 (7.1) |
NA |
| Patients likely unfit for HSCT,i n (%) |
61 (20.6) |
34 (64.2) |
| Other mental and physical comorbiditiesj (top 6 most prevalent), n (%) |
| Cardiac arrhythmias |
55 (18.6) |
20 (37.7) |
| Chronic pulmonary disease |
45 (15.2) |
22 (41.5) |
| Congestive heart failure |
32 (10.8) |
22 (41.5) |
| Diabetes |
74 (25.0) |
25 (47.2) |
| Hypertension |
134 (45.3) |
39 (73.6) |
| Valvular disease |
35 (11.8) |
17 (32.1) |
| During the observation period |
| Observation period duration,k months; mean ± SD [median] |
57.79 ± 36.31 [47.99] |
58.51 ± 24.07 [56.12] |